Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 7Leukemia, Myeloid, Acute 5Neuroblastoma 2Neoplasm Metastasis 2Tongue Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Myeloid 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Hepatoblastoma 1Gastrointestinal Stromal Tumors 1Fibrolamellar hepatocellular carcinoma 1

Interventions

Imatinib Mesylate 6Sunitinib 4ripretinib 2regorafenib 2Specimen Handling 2Paclitaxel 2Magnetic Resonance Spectroscopy 2IDRX-42 2trastuzumab deruxtecan 1pemigatinib 1olverembatinib 1envafolimab 1atezolizumab 1apatinib 1Temozolomide 1Surgical Instruments 1Sorafenib 1Rogaratinib 1Nivolumab 1Midazolam 1Laparoscopy 1Ipilimumab 1Cyclophosphamide 1CTLA-4 Antigen 1Blood Specimen Collection 1Biopsy 14-Aminopyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Stromal Tumors × Sorafenib × 90 days × Clear all
NCT00265798 2026-04-28

Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate

National Cancer Institute (NCI)

Phase 2 Active not recruiting
38 enrolled 9 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡